BridgeMD
Tests treatment safety and results for Osteoporosis
Official title Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients
ClinicalTrials.gov ID: NCT03755193
What this study is testing
What is SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"?
SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug" is an investigational medicine, being studied as a potential treatment for osteoporosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy: SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 120
You may be able to join if
- osteoporosis patients
You likely can't join if
- not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant
The study team makes the final eligibility decision.
Where it's taking place
- Matsumoto, Nagano, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 120 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Matsumoto, Nagano, Japan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.